Search hospitals > Montana > Kalispell
Kalispell Regional Medical Center
Claim this profileKalispell, Montana 59901
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Recurrence
510 reported clinical trials
3 medical researchers
Summary
Kalispell Regional Medical Center is a medical facility located in Kalispell, Montana. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Kalispell Regional Medical Center is involved with conducting 510 clinical trials across 547 conditions. There are 3 research doctors associated with this hospital, such as John M. Schallenkamp, Benjamin T. Marchello, and Alison Schneider.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
John M. SchallenkampBenefis Healthcare- Sletten Cancer Institute4 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
177 reported clinical trials
254 drugs studied
Benjamin T. MarchelloKalispell Regional Medical Center8 years of reported clinical research
Studies Breast Cancer
Studies Ovarian Cancer
6 reported clinical trials
20 drugs studied
Alison SchneiderGlacier View Research Institute - Endocrinology1 year of reported clinical research
Studies Diabetes
Studies Type 2 Diabetes
2 reported clinical trials
3 drugs studied
Clinical Trials running at Kalispell Regional Medical Center
Breast Cancer
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Prostate Cancer
Bladder Carcinoma
Pancreatic Cancer
Squamous Cell Carcinoma
Anal Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Kalispell Regional Medical Center?
Kalispell Regional Medical Center is a medical facility located in Kalispell, Montana. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Kalispell Regional Medical Center is involved with conducting 510 clinical trials across 547 conditions. There are 3 research doctors associated with this hospital, such as John M. Schallenkamp, Benjamin T. Marchello, and Alison Schneider.
Where is Kalispell Regional Medical Center located?
**Directions to Kalispell Regional Medical Center:**
- If heading north on U.S. Highway 93, turn right onto Sunnyview Lane.
- If traveling south on U.S. Highway 93, turn left onto Sunnyview Lane.
Who should I call to ask about financial aid or insurance network?
Kalispell Regional Medical Center, part of Logan Health, provides financial assistance for patients struggling to pay their medical bills. Patients can apply by filling out the Financial Assistance Application Form on the hospital's website. This program is open to all patients, regardless of insurance status. For more information, contact the financial assistance department at (406) 752-5125.
What insurance does Kalispell Regional Medical Center accept?
The Kalispell Regional Medical Center, also known as Logan Health, accepts a variety of insurance plans. This includes Blue Cross and Blue Shield of Montana (BCBSMT), which offers individual, family, Medicare, and Medicaid plans with COVID-19 coverage. Additionally, the hospital works with plans available through the Montana Health Insurance Marketplace, providing a comprehensive resource for residents to explore insurance options, understand subsidies, and learn about enrollment periods.
What awards or recognition has Kalispell Regional Medical Center received?
**Logan Health Medical Center**
- Recognized for its commitment to research and patient care.
- Actively participates in clinical trials to advance disease prevention, treatment, and detection.
- Awarded for outstanding performance as a rural community hospital, emphasizing its dedication to high-quality healthcare services in a non-urban setting.